Esketamine versus fentanyl as adjuncts to hepatic hilar nerve block for ambulatory percutaneous liver tumor ablation focusing on respiratory safety: protocol for a randomized controlled trial
Xiao Wang, Lijuan Yan, Jiaying Cai, Jianfei Wei, Zuo-Bing Zhang, Bin Yang
Frontiers in Pharmacology September 17, 2025 DOI: 10.3389/fphar.2025.1644029 (opens in new tab) via OpenAlex
Summary
AI-generated from the abstractA randomized controlled trial compares the risk of respiratory depression between esketamine-based and fentanyl-based analgesia during liver ablation guided by high-frequency harmonic scalpel. If esketamine shows superior respiratory safety, it could become a viable treatment option.
Study at a glance
| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Intervention | Fentanyl-based analgesia |
| Topics | Ketamine |
| Keywords | Medicine Fentanyl Anesthesia Randomized controlled trial Ambulatory |
| Citations | 1 |
| Key finding | The trial aims to provide Level I evidence comparing respiratory depression risk between esketamine-based and fentanyl-based analgesia during HHNB-guided liver ablation. |
Abstract
This trial aims to provide Level I evidence comparing the respiratory depression risk between esketamine-based and fentanyl-based analgesia during HHNB-guided liver ablation. Should esketamine prove to be demonstrably superior in terms of respiratory safety, HHNB-esketamine has the potential to be a viable treatment option.